Category: Enforcement Trends

Changes in the FDA

How the FDA and the 483 Have Changed

We asked our GMP Editor in Chief 3 important questions and got 3 insightful answers. Using decades worth of professional experience, she shares both the strengths and weaknesses of this thing we call the 483.

Read More »
FDA 483 Violations

Posted FDA 483 Violations | Week of 9/16/18

It’s 483 study time, and our GMP expert has extracted the key points in this week’s featured 483 posted by the FDA. Violations ranged from failing to provide scientific reasons for invalidating OOS results to failing to prevent colored residues on equipment.

Read More »
Warning Letters

Week of September 9th 2018 | FDA Sent These Warning Letters to Pharma/Device Companies

FDA posted 7 warning letters this week including 2 warning letters to Medtronic regarding non-conformance that resulted in a Class I recall of a defibrillator earlier in 2018. In addition, warning letters were issued to 1 firm in Canada and 1 firm in China. And, in the largest coordinated enforcement effort in the FDA’s history, 1,300 warning letters were issued to a single industry.

Read More »

Not Finding What You Are Looking For?



CONTACT US:      844-332-3320 |

Blog Categories
Knowledge Base

Can’t find what you are looking for? Contact us.